Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 924 of 3330
Next
>>
>
23076 to 23100 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
AU565	HER2amp	Luminal	Erlotinib	EGFR	ErbB	66.7	uM	5901.091	0.1225	-0.3289	1.9229
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.000171	uM	5902.091	0.9928	0.9876	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.000853	uM	5902.091	0.9499	0.9136	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.00427	uM	5902.091	1.0199	1.0342	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.0213	uM	5902.091	0.9816	0.9684	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.107	uM	5902.091	0.9464	0.9077	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.533	uM	5902.091	0.9053	0.8363	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	2.67	uM	5902.091	0.8506	0.7406	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	13.3	uM	5902.091	0.7911	0.6355	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	66.7	uM	5902.091	0.5780	0.2492	1.1648
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.000171	uM	5903.09	0.9899	0.9782	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.000853	uM	5903.09	0.9962	0.9918	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.00427	uM	5903.09	0.9496	0.8917	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.0213	uM	5903.09	0.9456	0.8831	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.107	uM	5903.09	0.9031	0.7923	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.533	uM	5903.09	0.8264	0.6288	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	2.67	uM	5903.09	0.7331	0.4319	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	13.3	uM	5903.09	0.6400	0.2372	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	66.7	uM	5903.09	0.4319	-0.1899	0.9291
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.0000853	uM	5904.092	1.1326	1.2991	0.8933
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.000427	uM	5904.092	0.9541	0.8975	0.8933
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.00213	uM	5904.092	1.0370	1.0829	0.8933
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.0107	uM	5904.092	1.0019	1.0044	0.8933
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.0533	uM	5904.092	0.9718	0.9370	0.8933
BT-20	TNBC	Basal A	Erlotinib	EGFR	ErbB	0.267	uM	5904.092	0.7511	0.4517	0.8933

|<
<<
Previous
Page 924 of 3330
Next
>>
>
23076 to 23100 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)